No improvement in recurrence-free survival vs chemotherapy alone.
Post hoc analysis of phase 3 trial shows benefit regardless of BRCA status.
An overview of the theme of ASCO 2019
HPV vaccination, testing best for preventing cervical cancer.
Radiotherapy shows good pelvic disease control rates.
Analysis of data from 12,633 patients with endometrial cancer.
Clinically relevant differences in demographics, biology, imaging, drug efficacy, etc.
Findings from ACTLACC trial.
SOLAR-1 phase 3 data may lead to alpelisib approval.
Surveillance with MRI plus mammography recommended.
Data from the multinational TRINOVA-3 trial.
Estimates of demand for chemotherapy and specialist workforce required by 2040.
Large meta-analysis of 125 studies, 20k patients.
33% additional risk reduction with a different safety profile.
Institute of Cancer Research survey finds 9% of UK patients have been denied access to a drug recommended by their clinician
Final 5-year analysis of IBIS-II prevention trial in women at high risk for breast cancer.
Study of more than 2800 women aged 35-39 years.
